Evidence map›Paper›PMID 38200561›Full record

ArticleArthritis research & therapy2024

Synovial tissue features associated with poor prognosis in inflammatory arthritis.

Ana Belén Azuaga, Andrea Cuervo, Raquel Celis, Beatriz Frade-Sosa, Juan C Sarmiento-Monroy, Virginia Ruiz-Esquide, José A Gómez-Puerta, Raimon Sanmartí, Julio Ramírez

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ana Belén AzuagaRheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain. abazuaga@clinic.cat.ORCID 0000-0002-8058-5154
Andrea CuervoRheumatology Department, Hospital General de Granollers, Granollers, Spain.
Raquel CelisRheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Beatriz Frade-SosaRheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Juan C Sarmiento-MonroyRheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Virginia Ruiz-EsquideRheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
José A Gómez-PuertaRheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Raimon SanmartíRheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Julio RamírezRheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain. fjramire@clinic.cat.ORCID 0000-0002-3068-7718
Hospital Clínic de Barcelona · ESHospital General de Granollers · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory arthritis encompasses a group of immune-mediated diseases characterized by chronic joint inflammation. Despite having pathogenic mechanisms in common, the prognosis of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and undifferentiated arthritis (UA) could be different regarding progression to chronic, to erosive, or to self-limited disease. Our aim was to evaluate the potential association of synovial tissue (ST) inflammatory cell infiltrate, the presence of ectopic lymphoid neogenesis (LN +) structures, and poor prognosis factors (PPF) in patients with RA, PsA, and UA.

methodsWe conducted a retrospective study including patients with active arthritis (RA, PsA, UA) who had ST obtained by rheumatological arthroscopy or ultrasound-guided biopsy. Clinical, demographic, and immunohistochemical data of the synovium was evaluated. Patients with biological therapy at the time of synovial biopsy were excluded. PPF in patients with RA and UA were defined by the presence of anti-cyclic citrullinated peptide antibodies and/or rheumatoid factor, development of bone erosions, or requirement of biological therapy during the follow-up. PPF in patients with PsA were defined as the presence of high levels of acute-phase reactants (ESR/CRP), dactylitis or nail involvement at the time of biopsy, development of bone erosion, or requirement of biological therapy during the follow-up.

resultsA total of 88 patients were included: 26 RA, 33 PsA, and 29 UA. All patients were followed up for 5 years after the biopsy. Fourteen (53.84%) RA patients had PPF, and 17 (65.38%) had LN + . LN + was associated with PPF (p 0.038) and biologic therapy initiation (p 0.018). A total of 14 (43.75%) PsA patients had PPF. CD15 infiltrate (410.68 [SD 477.63] cells/mm

conclusionsThe presence of LN + and higher CD15 + polymorphonuclear cells infiltrate was associated with PPF in RA and PsA, respectively. No associations were found for UA. These findings suggest a great heterogeneity of the ST features and its pathogenic implications in the subtypes of inflammatory arthritis.

Indexed as

Arthritis, PsoriaticArthritis, RheumatoidAnti-Citrullinated Protein AntibodiesHumansRetrospective StudiesSynovial MembraneAnti-Citrullinated Protein AntibodiesPoor prognosis factorPsoriatic arthritisRheumatoid arthritisSynovial tissueUndifferentiated arthritis

Identifiers

PMID38200561
PMCPMC10777612
OpenAlexW4390697842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.